Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MCRB

Seres Therapeutics Inc

Dec 08 • 04:00PM ET

1.09

Dollar change -0.01
Percentage change -0.91	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.13	Insider Own	24.81%	Shs Outstand	125.22M	Perf Week	1.87%
Market Cap	140.89M	Forward P/E	-	EPS next Y	-1.32	Insider Trans	-0.11%	Shs Float	97.19M	Perf Month	4.81%
Income	-141.27M	PEG	-	EPS next Q	-0.49	Inst Own	65.33%	Short Float / Ratio	24.04% / 6.62	Perf Quarter	-64.50%
Sales	127.24M	P/S	1.11	EPS this Y	57.39%	Inst Trans	15.17%	Short Interest	23.37M	Perf Half Y	-81.17%
Book/sh	-0.12	P/B	-	EPS next Y	-33.94%	ROA	-41.58%	Target Price	9.25	Perf Year	-82.16%
Cash/sh	1.31	P/C	0.83	EPS next 5Y	-	ROE	-538.57%	52W Range	0.91 - 6.87	Perf YTD	-80.54%
Dividend	-	P/FCF	-	EPS past 5Y	-0.93%	ROI	-74.01%	52W High	-84.13%	Beta	2.32
Dividend %	-	Quick Ratio	2.47	Sales past 5Y	49.53%	Gross Margin	88.72%	52W Low	19.78%	ATR	0.15
Employees	431	Current Ratio	2.71	Sales Q/Q	-91.00%	Oper. Margin	-102.89%	RSI (14)	44.17	Volatility	8.83% 12.98%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	23.83%	Profit Margin	-111.03%	Rel Volume	0.53	Prev Close	1.10
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 02 BMO	Payout	-	Avg Volume	3.53M	Price	1.09
Recom	1.86	SMA20	-2.24%	SMA50	-22.14%	SMA200	-72.43%	Volume	1,863,386	Change	-0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-23	Resumed	Oppenheimer	Outperform	$12
Apr-21-23	Initiated	JP Morgan	Neutral	$7
Jul-23-21	Downgrade	Goldman	Neutral → Sell	$24 → $7
May-18-21	Resumed	Goldman	Neutral	$24
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$30
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$32.50 → $27.50
Aug-18-20	Initiated	Piper Sandler	Overweight	$40
Aug-11-20	Upgrade	Jefferies	Hold → Buy	$4 → $29
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$8 → $41
Apr-30-19	Initiated	Jefferies	Hold	$7
Oct-22-18	Initiated	Chardan Capital Markets	Buy	$15
Oct-13-17	Initiated	Oppenheimer	Outperform	$19
Aug-04-17	Reiterated	H.C. Wainwright	Buy	$15 → $19
Feb-01-17	Reiterated	FBR & Co.	Outperform	$23 → $18
Aug-12-16	Reiterated	FBR Capital	Outperform	$43 → $23
Aug-01-16	Reiterated	H.C. Wainwright	Buy	$50 → $15
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Jul-29-16	Resumed	H.C. Wainwright	Buy	$50
Mar-30-16	Initiated	FBR Capital	Outperform	$40
Mar-03-16	Initiated	Guggenheim	Buy

Show Previous Ratings

Dec-07-23 07:46PM	Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023 (Business Wire)
Nov-28-23 09:18AM	Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET (Business Wire)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire) +7.72%
Nov-05-23 02:22PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:47AM	Loading…
Nov-02-23 08:47AM	Seres Therapeutics Inc (MCRB) Announces Q3 2023 Financial Results and Strategic Restructuring (GuruFocus.com) -35.25%
07:32AM	Seres Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST Net Sales of $7.6 Million (Business Wire)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire) -5.88%
Oct-30-23 05:30PM	Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST (Business Wire) +5.07%
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-12-23 07:00AM	Seres Therapeutics to Highlight VOWST Data at IDWeek (Business Wire) -12.72%
Oct-06-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.68%
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire) -9.66%
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
06:30AM	Loading…
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-08-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-07-23 10:00AM	Seres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-09-23 06:27AM	Investors Don't See Light At End Of Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Tunnel (Simply Wall St.) -6.06%
Aug-08-23 08:25AM	Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates (Zacks) -6.94%
07:19AM	Seres Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Aug-04-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 07:00AM	Seres Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
07:00AM	Seres Therapeutics to Host Second Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on August 8, 2023 (Business Wire)
Jul-14-23 04:01PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-07-23 10:17AM	Seres Therapeutics (NASDAQ:MCRB) shareholders have endured a 47% loss from investing in the stock five years ago (Simply Wall St.)
Jun-21-23 09:00AM	Seres Therapeutics Named to TIME100 Most Influential Companies List (Business Wire) +6.52%
Jun-17-23 03:45PM	Seres Therapeutics and Nestlé Health Science Present Late-Breaking Data on VOWST, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023 (Business Wire)
07:00AM	Loading…
Jun-09-23 07:00AM	Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference (Business Wire)
07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-23 07:00AM	Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection (Business Wire)
Jun-02-23 07:00AM	Seres Therapeutics to Present at Jefferies Healthcare Conference (Business Wire)
May-30-23 04:00PM	Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST (Business Wire)
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire)
May-10-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 08:15AM	Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Seres Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:00AM	Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome (Business Wire)
07:00AM	Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
May-08-23 07:00AM	Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting (Business Wire) -5.92%
02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com)
May-05-23 07:00AM	Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023 (Business Wire) +8.44%
Apr-29-23 09:03AM	Seres Therapeutics, Inc. (NASDAQ:MCRB) down to US$623m market cap, but institutional owners may not be as affected after a year of 3.1% returns (Simply Wall St.)
Apr-27-23 10:03AM	Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for (Zacks) -16.87%
07:00AM	Seres Therapeutics Announces $250 Million Debt Financing with Oaktree (Business Wire)
06:37AM	Here's a timeline of Seres' 12-year trek to one of the first microbiome drugs (American City Business Journals)
Apr-26-23 07:46PM	Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI (Business Wire)
06:23PM	UPDATE 2-US FDA approves Seres Therapeutics' pill for deadly C. difficile infections (Reuters)
10:02AM	Seres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-24-23 02:09AM	Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more \| Pro Recap (Investing.com)
Apr-20-23 09:45AM	Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon (Motley Fool)
Apr-14-23 05:10AM	Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength? (Zacks)
Apr-07-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-04-23 04:30PM	2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street (Motley Fool)
Mar-22-23 03:44AM	Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last? (Zacks)
Mar-09-23 07:00AM	Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference (Business Wire) -10.77%
Mar-08-23 10:45PM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript (Insider Monkey) +10.00%
Mar-07-23 10:28PM	Q4 2022 Seres Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:25AM	Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Business Wire)
Mar-03-23 04:00PM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-28-23 07:00AM	Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023 (Business Wire)
Feb-27-23 07:00AM	Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-14-23 07:00AM	Seres Therapeutics Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN (Business Wire)
Feb-08-23 07:28AM	Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Business Wire)
Feb-03-23 11:30AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-28-23 07:51AM	Seres Therapeutics' (NASDAQ:MCRB) investors will be pleased with their respectable 70% return over the last three years (Simply Wall St.)
Jan-13-23 07:00AM	Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-05-23 07:00AM	Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress (Business Wire)
Jan-04-23 07:00AM	Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-22 04:01PM	Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy (Business Wire)
Nov-08-22 05:35AM	Seres Therapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-02-22 08:35AM	Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -9.50%
07:00AM	Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (Business Wire)
Oct-27-22 07:00AM	Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022 (Business Wire)
Oct-26-22 07:00AM	Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review (Business Wire) +14.21%
Oct-23-22 03:30PM	Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings (Business Wire)
Oct-19-22 02:00PM	Seres Therapeutics ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association (Business Wire) -9.40%
Oct-12-22 07:00AM	Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting (Business Wire)
Sep-22-22 05:51AM	Limit lab construction in the world's biotech capital? A Cambridge proposal could do just that. (American City Business Journals)
Sep-08-22 07:00AM	Seres Therapeutics to Present at World Anti-Microbial Resistance Congress (Business Wire) +6.17%
Sep-07-22 07:00AM	Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection (Business Wire) +17.04%
Aug-29-22 06:43AM	Calculating The Intrinsic Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB) (Simply Wall St.)
Aug-08-22 06:11AM	Analysts Are Betting On Seres Therapeutics, Inc. (NASDAQ:MCRB) With A Big Upgrade This Week (Simply Wall St.)
Aug-04-22 07:00AM	Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference (Business Wire) +9.66%
Aug-03-22 08:15AM	Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.54%
07:00AM	Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (Business Wire)
Jul-28-22 07:00AM	Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022 (Business Wire)
Jul-19-22 12:21PM	Do Institutions Own Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares? (Simply Wall St.) +9.14%
Jun-30-22 07:30AM	Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock (Business Wire) +8.89%
Jun-19-22 10:47AM	Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 12% this week, taking one-year losses to 87% (Simply Wall St.)
Jun-07-22 12:18PM	Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug (Benzinga) +28.79%
07:00AM	Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection (Business Wire)
Jun-01-22 07:00AM	Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
May-23-22 08:00AM	Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman (GlobeNewswire) -7.56%
May-22-22 03:15PM	Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting (Business Wire)
May-10-22 07:00AM	Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting (Business Wire) +5.61%
May-05-22 09:30AM	Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Slashed This Year's Revenue Estimates By 59% (Simply Wall St.) -7.84%

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shaff Eric D.	CEO and President	Oct 30	Sale	1.35	8,552	11,545	115,620	Oct 31 09:40 PM
von Moltke Lisa	See Remarks	Oct 30	Sale	1.35	4,232	5,713	9,513	Oct 31 09:36 PM
DesRosier Thomas	Chief Legal Officer and EVP	Oct 30	Sale	1.35	4,156	5,611	113,891	Oct 31 09:39 PM
Arkowitz David	Chief Financial Officer	Oct 30	Sale	1.35	4,066	5,489	175,756	Oct 31 09:39 PM
Ege David S.	See Remarks	Oct 30	Sale	1.35	4,066	5,489	66,991	Oct 31 09:39 PM
Henn Matthew R.	See Remarks	Oct 30	Sale	1.35	3,886	5,246	56,356	Oct 31 09:36 PM
Young Teresa L.	See Remarks	Oct 30	Sale	1.35	2,907	3,924	8,454	Oct 31 09:40 PM
Cloghessy Paula	See Remarks	Oct 30	Sale	1.35	2,904	3,920	45,684	Oct 31 09:43 PM
Cloghessy Paula	See Remarks	Oct 27	Option Exercise	0.00	9,418	0	48,588	Oct 31 09:43 PM
Young Teresa L.	See Remarks	Oct 27	Option Exercise	0.00	11,361	0	11,361	Oct 31 09:40 PM
Shaff Eric D.	CEO and President	Oct 27	Option Exercise	0.00	27,838	0	124,172	Oct 31 09:40 PM
Arkowitz David	Chief Financial Officer	Oct 27	Option Exercise	0.00	13,209	0	179,822	Oct 31 09:39 PM
Ege David S.	See Remarks	Oct 27	Option Exercise	0.00	11,361	0	71,057	Oct 31 09:39 PM
DesRosier Thomas	Chief Legal Officer and EVP	Oct 27	Option Exercise	0.00	13,501	0	118,047	Oct 31 09:39 PM
Henn Matthew R.	See Remarks	Oct 27	Option Exercise	0.00	12,623	0	60,242	Oct 31 09:36 PM
von Moltke Lisa	See Remarks	Oct 27	Option Exercise	0.00	13,745	0	13,745	Oct 31 09:36 PM
Ege David S.	See Remarks	Apr 28	Sale	5.19	7,038	36,527	59,696	May 01 04:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MCRB

Seres Therapeutics Inc

Upgrade your FINVIZ experience